Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Key Takeaways Major U.S. equities indexes were little changed Monday morning, ahead of retail sector earnings reports and ...

GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both Novo Nordisk's GLP-1 drugs, Ozempic and Wegovy, at a cash price of $499 per month.

Patients who are prescribed Wegovy or Ozempic can now use GoodRx to access the medications at just $499 a month if they skip ...

GoodRx (GDRX) is joining in on the GLP-1 action with an announcement on Monday that it will begin selling both of Novo Nordisk's (NVO) GLP-1 drugs, Ozempic for diabetes and Wegovy for weight loss, at ...

Here are some of the biggest premarket U.S. stock movers today: Palo Alto Networks (NASDAQ: PANW) stock rose 0.4%, with the ...

Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...

People who are prescribed Ozempic to treat type 2 diabetes, but whose insurance does not cover it, or who don’t have ...

Several months after unveiling its direct-to-consumer NovoCare Pharmacy service with the launch of a $499 cash-pay option for ...

Novo Nordisk is working with GoodRx to offer a month’s supply of Ozempic for $499, or about half the list price, for self-paying patients.  Ozempic, a drug approved for Type 2 diabetes, cardiovascular ...